Idiopathic pulmonary fibrosis (IPF), a chronic lung disease claiming approximately 30,000 to 40,000 victims every year, is characterized by rapid lung degeneration and a dismal median survival of 3-5 years after diagnosis. Despite a clear need for treatments that can improve this prognosis, there are currently only two therapies available for the treatment of IPF. While these two therapies have been shown to slow disease progression, neither treatment can actually halt lung degeneration or reverse lung tissue remodeling.
Post-doc’s experience around data generation, use and curation.
FlowJo, LLC has created a suite of products that enable ease, efficiency and standardization in the clinical flow cytometry laboratory, from sample collection through final report.
Oct 08, 2017 | Flow Cytometry